03:40:56 EDT Sun 25 Sep 2022
Enter Symbol
or Name

Login ID:
M Pharmaceutical Inc (2)
Symbol MQ
Shares Issued 14,237,343
Close 2015-09-16 C$ 0.13
Recent Sedar Documents

ORIGINAL: M Pharmaceutical to Request DTC Eligibility to Improve Liquidity on the OTCQB

2015-09-17 09:32 ET - News Release

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/17/15

M Pharmaceutical Inc. (CSE:MQ)(OTCQB:MPHMF)(FRANKFURT:T3F2) (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, today announced that it will engage a participant of the Depository Trust Company ("DTC") to request that the Company's securities become eligible for depository services. DTC Eligibility allows for a Company's securities to be traded electronically between brokerage accounts in the U.S.

Matthew Lehman, M Pharmaceutical's CEO: "DTC Eligibility is a significant step toward improving the liquidity of our stock in the U.S. market. This will allow for electronic trading of M Pharma's securities via the OTCQB which, as of this time, is not possible."

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company acquired the exclusive rights to three technologies invented by Dr. Martin Mintchev at the University of Calgary: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward-Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

M Pharmaceutical Inc.
Investor Relations
+1 604 428 0511

© 2022 Canjex Publishing Ltd. All rights reserved.